The role of the glycocalyx in matrix stiffness-mediated vascular disease

Information

  • Research Project
  • 10429324
  • ApplicationId
    10429324
  • Core Project Number
    F32HL145913
  • Full Project Number
    3F32HL145913-02S1
  • Serial Number
    145913
  • FOA Number
    PA-18-670
  • Sub Project Id
  • Project Start Date
    5/28/2019 - 5 years ago
  • Project End Date
    8/27/2021 - 3 years ago
  • Program Officer Name
    MEADOWS, TAWANNA
  • Budget Start Date
    6/21/2021 - 3 years ago
  • Budget End Date
    8/27/2021 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
    S1
  • Award Notice Date
    6/21/2021 - 3 years ago

The role of the glycocalyx in matrix stiffness-mediated vascular disease

Project Summary With increased age and/or hypertension, arteries lose elasticity and thicken, giving rise to a stiffened arterial wall. Arterial stiffness is a key underlying risk factor and is a hallmark of age/hypertension-related cardiovascular diseases such as atherosclerosis. Endothelial cell (EC) dysfunction, characterized by increased proliferation, permeability and inflammation is at the heart of the mechanism driving vascular diseases. ECs lining the vasculature are highly responsive to mechanical forces and respond to these external forces by altering gene expression and downstream signaling pathways. In the vasculature, disturbed blood flow patterns promote the expression of pro-inflammatory, pro-proliferative genes leading to EC dysfunction and atherosclerosis. The glycocalyx is a glycan complex that is expressed on the surface of EC and is known to function as a mechanosensor that translates external forces into genetic and functional changes in EC. The glycocalyx is a vital element of a functional endothelium, where it regulates EC homeostasis and integrity. Intriguingly, at athero-prone regions, disturbed blood flow promotes loss of the glycocalyx, leading to EC dysfunction. Additionally, in hypertensive mice, the expression of proteins in synthetic pathways for glycocalyx components are reduced. These observations suggest that there is a correlation between the expression of glycolcayx components with the development of hypertension. Whilst stiffness-mediated tension is another mechanical force that promotes EC dysfunction and vascular disease, it is not known whether the effects of stiffness are translated into genetic and cellular changes through the glycocalyx machinery. Consistent with this, the effect of hypertension on the glycocalyx has not been reported to date. Preliminary work from our lab has demonstrated that glycocalyx expression is reduced on the surface of EC cultured on stiff polyacrylamide gels (10 kPa, mimicking physiological stiffness of aged/hypertensive arteries) vs. EC cultured on soft gels (2.5 kPa, mimicking physiological stiffness of young/normotensive arteries), indicating that increased stiffness inhibits glycocalyx expression. Taken together, here we hypothesize that age/hypertension-related increases in arterial stiffness reduce glycocalyx expression from ECs, leading to EC dysfunction and vascular disease.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    F32
  • Administering IC
    HL
  • Application Type
    3
  • Direct Cost Amount
    21120
  • Indirect Cost Amount
  • Total Cost
    21120
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
    NHLBI:21120\
  • Funding Mechanism
    TRAINING, INDIVIDUAL
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CITY COLLEGE OF NEW YORK
  • Organization Department
    ENGINEERING (ALL TYPES)
  • Organization DUNS
    603503991
  • Organization City
    NEW YORK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    100367207
  • Organization District
    UNITED STATES